Company: TAK
Filing Date: 2025-06-25
Form Type: 20-F
Source: 0001395064-25-000095
Chunk: 117

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-06-25
Form: 20-F
Item: Item 5
Chunk 117
---
                                                          ¥                              1,054.9            ¥      1,162.6      ¥                         10.2           4.9  
  Core finance income and (expenses), net                                        (142.0)                                     (140.7)                   1.3                      (0.9)         (4.5)  
  Core share of profit of investments accounted for using the equity method      5.9                                             1.1                   (4.8)                   (81.2)        (82.2)  
  Core profit before tax                                                         918.8                                                    1,023.1      104.3                     11.3           5.8  
  Core income tax expenses                                                       (161.9)                                     (247.3)                   (85.4)                    52.7          48.7  
  Core net profit for the year                                                   756.9                                         775.8                   18.9                       2.5         (3.4)  
  Core net profit for the year attributable to owners of the Company             ¥                                756.8            ¥        775.6      ¥                          2.5         (3.4)  

During the periods presented, these items fluctuated as follows:

Core Net Finance Expenses

Core Net Finance Expenses were JPY 140.7 billion (JPY -1.3 billion and-0.9% AER,-4.5% CER).

Core Share of Profit of Investments Accounted for Using the Equity Method

Core Share of Profit of Investments Accounted for Using the Equity Method was JPY 1.1 billion (JPY -4.8 billion and-81.2% AER,-82.2% CER).

Core Profit Before Tax

Core Profit Before Tax was JPY 1,023.1 billion (JPY +104.3 billion and+11.3% AER,+5.8% CER).

Core Income Tax Expenses

Core Income Tax Expenses were JPY 247.3 billion (JPY +85.4 billion and+52.7% AER,+48.7% CER). The increase was primarily due to higher core pretax earnings and the reassessment of recoverability of deferred tax assets leading to higher core tax expenses during the fiscal year ended March 31, 2025 as well as a reduction of tax expense during the fiscal year ended March 31, 2024 due to